Endonovo Therape Financials

Endonovo Therape (ENDV) reported $135K in total revenue for fiscal year 2022. This represents a 85.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Endonovo Therape (ENDV) revenue grew by 85.2% year-over-year, from $73K to $135K in fiscal year 2022.

No, Endonovo Therape (ENDV) reported a net income of -$18.5M in fiscal year 2022, with a net profit margin of -13649.2%.

Endonovo Therape (ENDV) had EBITDA of -$2.6M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2022, Endonovo Therape (ENDV) had $98 in cash and equivalents against $7.2M in long-term debt.

Endonovo Therape (ENDV) had a gross margin of 92.6% in fiscal year 2022, indicating the percentage of revenue retained after direct costs of goods sold.

Endonovo Therape (ENDV) had an operating margin of -2411.7% in fiscal year 2022, reflecting the profitability of core business operations before interest and taxes.

Endonovo Therape (ENDV) had a net profit margin of -13649.2% in fiscal year 2022, representing the share of revenue converted into profit after all expenses.

Endonovo Therape (ENDV) generated -$679K in operating cash flow during fiscal year 2022, representing cash generated from core business activities.

Endonovo Therape (ENDV) had $1.3M in total assets as of fiscal year 2022, including both current and long-term assets.

Endonovo Therape (ENDV) had 213M shares outstanding as of fiscal year 2022.

Endonovo Therape (ENDV) had a current ratio of 0.00 as of fiscal year 2022, which is below 1.0, which may suggest potential liquidity concerns.

Endonovo Therape (ENDV) had a debt-to-equity ratio of -0.22 as of fiscal year 2022, measuring the company's financial leverage by comparing total debt to shareholder equity.

Endonovo Therape (ENDV) had a return on assets of -1441.9% for fiscal year 2022, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2022 data, Endonovo Therape (ENDV) had $98 in cash against an annual operating cash burn of $679K. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Endonovo Therape (ENDV) has negative shareholder equity of -$32.2M as of fiscal year 2022, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Endonovo Therape (ENDV) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals.

Endonovo Therape (ENDV) has an earnings quality ratio of 0.04x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation.

Endonovo Therape (ENDV) has an interest coverage ratio of -2.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline.